Miriam Padilla, MD
Family Medicine · Venice, CANPI 1104833979
Payments from drug & device makers
Across 412 payments — averaging $234.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$63K
- Medtronic$18K
- Lilly USA, LLC$11K
- Boehringer Ingelheim$2K
- Novo Nordisk$720
- Abbott$380
- plus $2K from 27 others
What the payments were for
- Consulting fees$1,4181%
- Speaking & faculty fees$86,52089%
- Travel & lodging$3,9174%
- Food & beverage$4,8675%
- Education$230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 109 | $62,977 |
| Medtronic(2 entities) | 54 | $17,915 |
| Lilly USA, LLC | 32 | $11,281 |
| Boehringer Ingelheim | 7 | $1,883 |
| Novo Nordisk | 84 | $720 |
| Abbott | 26 | $380 |
| Dexcom, Inc. | 11 | $189 |
| Xeris Pharmaceuticals, Inc. | 10 | $157 |
| Antares Pharma, Inc. | 10 | $130 |
| Merck | 9 | $123 |
| Amarin Pharma, Inc. | 7 | $104 |
| Tandem Diabetes Care, Inc. | 5 | $98 |
| Mannkind Corporation | 7 | $94 |
| Corcept Therapeutics | 6 | $94 |
| Novartis | 5 | $84 |
| Insulet Corporation | 4 | $57 |
| Neurocrine Biosciences, Inc. | 2 | $47 |
| Ascensia Diabetes Care US Inc. | 2 | $45 |
| Amgen | 2 | $43 |
| Sanofi-aventis U.S. LLC | 3 | $42 |
| Recordati_rare_diseases_inc. | 3 | $39 |
| Cequr Corporation | 2 | $37 |
| Ipsen Biopharmaceuticals, Inc | 1 | $34 |
| Bayer | 2 | $29 |
| Lundbeck LLC | 1 | $22 |
| Madrigal Pharmaceuticals | 1 | $19 |
| BETA Bionics, Inc. | 1 | $17 |
| Lifescan, Inc. | 1 | $17 |
| Chiesi USA, Inc. | 1 | $15 |
| Companion Medical, Inc. | 1 | $14 |
| Boston Scientific | 1 | $14 |
| Sequel Med Tech, LLC | 1 | $14 |
| Zealand Pharma US, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$61,737
- Minimed 630G$9,125
- MOUNJARO$4,200
- InPen$2,875
- Minimed 670G System$2,390
- JARDIANCE$2,288
- Minimed 770G System$1,250
- MINIMED 770G$1,170
How this compares
$96,745 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 59 | $95,045 |
| OzempicSemaglutide | 45 | $81,591 |
| JardianceEmpagliflozin | 55 | $70,239 |
| TymlosAbaloparatide | 22 | $57,703 |
| FarxigaDapagliflozin Propanediol | 67 | $52,432 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $25,600 |
| MounjaroTirzepatide | 14 | $14,533 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $8,020 |
| VascepaIcosapent Ethyl | 11 | $6,843 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $5,391 |
| Liothyronine Sodium | 109 | $4,247 |
| Levothyroxine Sodium | 274 | $3,659 |
| Humalog Kwikpen U-100Insulin Lispro | 12 | $2,729 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 17 | $1,883 |
| Metformin Hcl ErMetformin Hcl | 51 | $1,685 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $11,281 | $109,57773 claims |
| Novo NordiskOzempic | $720 | $81,59145 claims |
| Boehringer IngelheimJardiance | $1,883 | $70,23955 claims |
| AstraZenecaFarxiga | $62,977 | $52,43267 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.
Other family medicine in Venice
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.